InflaRx N.V.
IFRX Nasdaq· Pharmaceutical Preparations
Last close · Oct 27, 2026
$1.66
KIRA · Stoqly’s AI analyst, in plain words
- InflaRx N.V. had $0.0M of revenue in fiscal 2025, down 81.5% on the year before.
- InflaRx N.V. lost $51.5M in fiscal 2025.
Market cap
$112M
P/E
—
Revenue
$0.0M
Net income
−$51.5M
Free cash flow
—
Operating margin
—
InflaRx N.V. in 30 seconds · fiscal 2025
Are sales growing?
−81.5%
No. Sales fell 81.5% last year.
Does it make a profit?
−155,465.0%
No. It lost money last year.
How healthy are the accounts?
1 / 8
Weak. It passes 1 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What InflaRx N.V. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Mar 20, 2026
- Legal name
- InflaRx N.V.
- CIK
- 0001708688
InflaRx N.V. · IFRX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | −$33.9M | $0.1M | $0.2M | $0.0M |
| Revenue growth | — | — | — | 163.0% | −81.5% |
| Gross margin | — | — | −744.0% | −1,900.2% | −24,659.5% |
| Operating margin | — | 100.0% | −71,207.8% | — | — |
| Net income | −$54.0M | −$31.0M | −$46.1M | −$49.8M | −$51.5M |
| Net margin | — | 91.5% | −67,655.0% | −27,777.3% | −155,465.0% |
| Diluted EPS | −$1.30 | −$0.70 | −$0.84 | −$0.84 | −$0.77 |
| Cash | |||||
| Cash from operations | −$47.2M | −$35.5M | −$40.9M | −$52.5M | −$39.8M |
| Share count change | 53.8% | 6.2% | 24.3% | 7.2% | 14.2% |
| Debt and strength | |||||
| Cash and short-term investments | $29.7M | $17.3M | $14.1M | $19.1M | $18.8M |
| Debt incl. finance leases | $0.0M | — | — | — | — |
| Shareholders' equity | $119M | $7.7M | $8.2M | $7.7M | $8.4M |
| Current ratio | 5.1x | 7.5x | 6.5x | 5.1x | 4.1x |
| Interest coverage | −4,435.9x | −1,383.0x | −2,713.1x | — | — |
| Returns and quality | |||||
| Return on capital | −49.7% | — | — | — | — |
| Return on equity | −50.2% | −48.8% | −580.5% | −627.3% | −637.0% |
| Return on tangible equity | −45.4% | −408.2% | −565.6% | −644.7% | −610.7% |
| Piotroski F-score | — | — | 2 | 1 | 1 |
| Altman Z'' | 1.4 | −3.9 | −4.7 | — | — |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
InflaRx N.V. · IFRX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.66 a share, the company is worth $112M.
Source: SEC EDGAR XBRL filings (CIK 0001708688). Data updated October 24, 2026. Filed in EUR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.